PDS Biotechnology Corporation Common Stock (PDSB) is a publicly traded Healthcare sector company. As of May 21, 2026, PDSB trades at $1.07 with a market cap of $65.86M and a P/E ratio of -1.43. PDSB moved +3.50% today. Year to date, PDSB is +20.71%; over the trailing twelve months it is -36.81%. Its 52-week range spans $0.51 to $4.29. Analyst consensus is strong buy with an average price target of $7.50. Rallies surfaces PDSB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
PDS Biotechnology Extends Cash Runway to Q3 2027, Advances PDS0101 to Phase 2: PDS Biotechnology extended its cash runway into the third quarter of 2027 after completing a financing round in Q1 2026. The company advanced its lead immuno-oncology candidate PDS0101 into Phase 2 head-and-neck cancer trials with pembrolizumab, targeting interim efficacy readouts by late 2026.
| Metric | Value |
|---|---|
| Price | $1.07 |
| Market Cap | $65.86M |
| P/E Ratio | -1.43 |
| EPS | $-0.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.29 |
| 52-Week Low | $0.51 |
| Volume | 1.72K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-34.50M |
| Gross Margin | 0.00% |
3 analysts cover PDSB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.50.